A preliminary study of apparent diffusion coefficient in chemotherapy-induced liver damage

Area of Science:

• Radiology and Medical Imaging
• Oncology
• Hepatology

Background:

• Chemotherapy can induce liver damage, affecting liver function and potentially leading to conditions like fatty liver.
• Monitoring chemotherapy-induced liver injury is crucial for patient management and treatment adjustments.

Purpose of the Study:

• To investigate changes in hepatic apparent diffusion coefficient (ADC) in patients undergoing chemotherapy.
• To determine if hepatic ADC can serve as a biomarker for chemotherapy-induced liver damage.

Main Methods:

• A study involving 54 chemotherapy patients and 10 controls.
• Measurement of hepatic ADC values using diffusion-weighted imaging.
• Assessment of serum alanine aminotransferase (ALT) activity and presence of fatty liver in patients.

Main Results:

• Hepatic ADC was significantly lower in chemotherapy patients compared to controls.
• Lower hepatic ADC values were observed in patients with fatty liver and abnormal ALT activity.
• Hepatic ADC did not show a significant correlation with ALT activity in patients.

Conclusions:

• Hepatic ADC can distinguish patients likely to have chemotherapy-induced liver damage, indicated by abnormal ALT or fatty liver.
• While not directly correlated with ALT, ADC serves as a valuable imaging biomarker for liver health during chemotherapy.
• Further research is needed to fully elucidate the mechanisms underlying these observed changes.